Our Culture
What you believe and what you value as an organization matters. Discover the DNA of our firm.
2016
Sands Capital (2016 - 2022)
Arlington, VA | Managing Partner
Enzymatics Inc. (2013 - 2015)
Beverly, MA | CEO
Stemgent Inc. (2008 - 2013)
Cambridge, MA | Founder, CEO
Upstate Inc. (2002 - 2004)
Charlottesville, VA | President
University of Virginia
MBA | Darden School
University of Surrey
Chemical Engineering
Ian is a serial entrepreneur and has 20 years of experience starting and investing in life sciences technology businesses as an angel, venture and private equity investor. Ian has served in many roles as a founder, CEO, CFO, COO, chairman, director, and advisor to a number of privately-held Life Science product and service businesses. He has focused on the cell signaling, drug screening, genomics and sequencing, and cell culture and modification segments, at all stages of business development from initiation through profitability to trade sell. Prior to joining Sands Capital, Ian was the Chairman and CEO of Enzymatics Inc., founder and CEO of Stemgent, Inc., a stem and iPS cell life sciences tool, and President of Upstate Inc., a leading provider of cell signaling research products and services. Ian was also a founding investor in Firefly Bioworks and Genometry, both SCV investments. Ian has a degree in Chemical Engineering from University of Surrey and has a MBA from the Darden School at the University of Virginia.
An independent, staff-owned firm founded in 1992 and headquartered in the Washington, D.C. area with offices in London and Singapore, Sands Capital managed more than $46 billion in client assets as of September 30, 2023.
For institutional and professional investors only. Investment advisory fees are described in Part II of the adviser’s Form ADV.
